HOME
ADA / IMMUNOGENICITY
CUSTOMPLEX
TECHNOLOGY
ASSAY MENU
ABOUT US
Policy and Objectives
Leadership
Board
Investors
News and Media
Careers
Support
Contact Us
» Corporate
Letter from the CEO
Quality Policy and Objectives
» Leadership
Peter Lea, Ph.D.
Claude Ricks
Andrew Morris, M.Sc., MBA
Kate Smith
Jaymie R. Sawyer, Ph.D.
Russell Peloquin
Darryl Burke
Sasi Mudumba, Ph.D.
» Board of Directors
» Investors
» News & Media
Press Releases 2013
Press Releases 2012
Press Releases 2011
Press Releases 2010
Press Releases 2009
Press Releases 2008
» Career Openings
» Contact Us
Press Releases 2013
May 3, 2013
SQI Announces Closing Of Private Placement
April 30, 2013
SQI Announces Private Placement Of Up To Cdn $3.760 Million
March 25, 2013
SQI Diagnostics and Algorithme Pharma Provide Update on Multiplex Heparin Immunogenicity Assay
February 14, 2013
SQI Diagnostics Reports First Quarter Financial Results
January 24, 2013
SQI Diagnostics and Algorithme Pharma to Develop Multiplex Heparin Immunogenicity Assay
January 10, 2013
SQI Diagnostics Announces Stock Option Grants
